AbbVie Business Development at a Glance

March 12, 2018

AbbVie Stock

AbbVie Inc Company Type: Large Pharma
Region: United States, Worldwide
Cash Position: USD 9 789M
Therapeutic Focus: Immunology, Oncology, Neuroscience, Virology, General Medicine


Deal Activity

AbbVie Data

Figure 1. AbbVie Inc. In-Licensing Deals and Acquisitions, 2013 through Present (March 2018)

Recent Deal Highlights:

COLLABORATION WITH VOYAGER THERAPEUTICS FOR ALZHEIMERS AND TAU-RELATED NEURODEGENERATIVE DISORDERS

Upfront: USD 69M | Therapeutic Area: Neuroscience | Date: February 2018

PRESS

COLLABORATION WITH ALECTOR FOR ALZHEIMERS AND NEURODEGENERATIVE DISORDERS

Total Size: USD 225M | Upfront: USD 205M | Therapeutic Area: Neuroscience | Date: October 2017

PRESS

COLLABORATION WITH HARPOON THERAPEUTICS FOR TRI-SPECIFIC T-CELL ACTIVATING CONSTRUCT PLATFORM

Therapeutic Area: Oncology | Date: October 2017

PRESS

R&D PIPELINE

AbbVie Pipeline

Figure 2. AbbVie Inc. R&D Pipeline at Present (March 2018)

Products from Recent Deals:

ACQUIRED STEMCENTRX ANTIBODY DRUG CONJUGATE ROVA-T

Disease Area: Oncology | Status: Small Cell Lung Cancer Phase I | R/R Ovarian Cancer Phase I | Advanced Solid Tumors Phase I | Breast Cancer Phase I | Colorectal Cancer Phase I | Colorectal Or Gastric Cancer Phase I

BOEHRINGER INGELHEIM PARTNERED IL-23 ANTIBODY

Disease Area: Immunology | Status: Crohn's Disease Phase III | Psoriasis Phase III | Ulcerative Colitis Phase III | Generalized Pustular or Erythrodermic Psoriasis Phase III

GALAPAGOS PARTNERED CYSTIC FIBROSIS TRANSMEMBRANE REGULATORS

Disease Area: General Medicine | Status: Cystic Fibrosis F508del homozygous Phase II | Cystic Fibrosis Phase I

BUSINESS DEVELOPMENT TEAM

Where did the data come from? The data and visualizations in this post come from the MotionHall OutMatch predictive out-licensing software.

How can I see more? Join the MotionHall platform today to access business development insights gleaned from data and predictive analytics.